EN | UA
EN | UA

Help Support

Back

Universal multi-allergen immunotherapy formula improves allergic rhinitis symptoms

Multi-Allergen Subcutaneous Immunotherapy Multi-Allergen Subcutaneous Immunotherapy
Multi-Allergen Subcutaneous Immunotherapy Multi-Allergen Subcutaneous Immunotherapy

What's new?

In people with allergic rhinitis, the usage of multi-allergen immunotherapy is linked with improvements in symptoms.

A universal low-dose multi-allergen immunotherapy (MAIT) regimen is well-tolerated and leads to remarkable improvements in symptoms of moderate to severe allergic rhinitis. This randomized double-blind pilot study was performed to determine the safety and effectiveness of an all-purpose, MAIT formulation for allergic rhinitis management. A new, subcutaneous MAIT regimen comprising a special combination of greater than 150 aeroallergens, encompassing several cross-reactive species, was administered in a double-blind, placebo-controlled study to individuals with moderate-severe perennial and seasonal allergic rhinitis.

Regardless of whatever specific skin tests were positive, every patient received the same universal immunotherapy regimen. The usage of rescue drugs, mini-Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), validated clinical evaluations, and the Total Nasal Symptom Score (TNSS) were the key endpoints at 8 and 12 weeks of treatment. In total, 31 individuals were randomly allocated to get MAIT or placebo. MAIT reduced the combined TNSS and rescue medication score (Daily Combined Score [DCS]) by -4.6 (-58%) as opposed to -1.5 (-20%) for the placebo (P = 0.037) by week 12.

The mini-RQLQ dropped by -34.9 (-68%) with MAIT when compared to -17 (-42%) with placebo. Mild adverse effects were rare and occurred with identical frequency in each arm. The symptoms of allergic rhinitis considerably improved after using a universal, global, high species abundance, MAIT formula. The outcomes of this study should be viewed as preliminary.

Source:

Annals of Allergy, Asthma & Immunology

Article:

Randomized Double Blind Pilot Study of Universal, Species Abundant, Multi-Allergen Subcutaneous Immunotherapy for Moderate-Severe Allergic Rhinitis

Authors:

Jody Tversky et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: